Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21838602 | 0.92 | KMO (0.37) | AKR1C3AKR1C1HSD11B1POLQ | |
| SCHEMBL21838641 | 0.92 | KMO (0.37) | AKR1C3AKR1C1HSD11B1POLQ | |
| SCHEMBL21838644 | 0.87 | SCN9A (0.39) | HSD11B1RIPK1 | |
| SCHEMBL21838555 | 0.86 | HSD11B1 (0.40) | HSD11B1ALDH1A1POLQ | |
| SCHEMBL21838645 | 0.85 | SCN9A (0.45) | — | |
| SCHEMBL21838629 | 0.85 | SCN9A (0.45) | — | |
| SCHEMBL21838609 | 0.83 | SCN9A (0.41) | — | |
| SCHEMBL1025952 | 0.77 | HSD11B1 (0.52) | AKR1C3AKR1C1HSD11B1SIGMAR1RIPK1 | |
| SCHEMBL1025951 | 0.77 | HSD11B1 (0.52) | AKR1C3AKR1C1HSD11B1SIGMAR1RIPK1 | |
| SCHEMBL1029213 | 0.75 | MAOA (0.46) | MAOASIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | AKR1C3 327/4885AKR1C1 751/4885HSD11B1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.